Corporate News
Posting of Annual Report to Shareholders and Notice of Annual General Meeting
23 May 2022
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, confirms that the Annual Report and Accounts for the year ended 31 December 2021 and the Notice of Annual General Meeting (“AGM”)
have been posted to shareholders today. A copy of the 2021 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20:
https://investors.genincode.com/investors/annual-interim-reports
The AGM will be held in person at the offices of Walbrook PR, 75 King William Street, London EC4N 7BE on Thursday, 23 June 2022 at 2.00 p.m.
The Directors consider that the proposed resolutions contained in the Notice of Annual General Meeting are in the best interests of the Company and shareholders as a whole and unanimously recommend that you vote in favour of them, as they intend to do in respect of their own shareholdings.
For more information visit www.genincode.com
| GENinCode Plc | www.genincode.com or via Walbrook PR | |
|---|---|---|
| Matthew Walls, CEO | ||
| Paul Foulger, CFO | ||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |
| Alex Price / Ben Maddison / Richard Short | ||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny | ||
| Dale Bellis / Michael Johnson (Sales) | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or | |
| Anna Dunphy / Paul McManus / Louis Ashe-Jepson | [email protected] | |
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic
heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised
blood glucose, raised blood lipids, and overweight and obesity. These “intermediate risks factors” can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive
environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.
Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to
ensure that those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.
Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their ‘ABC’ (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.